On 27 April, Regeneron and Sanofi published provisional results from the Phase II section of an ongoing Phase II/III clinical trial assessing Kevzara (sarilumab), in hospitalised patients with severe or critical respiratory illness caused by Covid-19.

The randomised trial compared the drug, administered intravenously at two different doses of 200mg and 400mg, with placebo. Read more here.